Why Maximus is on investors’ radar today

Maximus (MMS) is drawing attention after recent trading that leaves the stock about flat over the past year, but with a decline over the past 3 months and year to date performance under pressure.

The recent 30 day share price return of 4.83% contrasts with a 90 day share price decline of 30.56%, while the 1 year total shareholder return of 0.38% decline points to fading momentum after earlier resilience.

If Maximus has you reassessing where the next move could come from, it may be worth scanning for other opportunities using our screener of 18 top founder-led companies

With the shares trading near US$65.58 and internal models pointing to a 59.54% intrinsic discount alongside a large gap to analyst targets, you have to ask: is Maximus undervalued, or is the market already pricing in its future growth?

Most Popular Narrative: 40.4% Undervalued

Compared with the last close at $65.58, the most followed narrative anchors on a fair value of $110, implying a wide gap that the market has yet to close.

The company's ongoing investments in digital, workflow automation, and AI (notably for complex health and claims processing), along with recent inorganic growth and expanded pipeline in federal and state markets, are laying the groundwork for sustainable earnings growth above the rate of revenue growth, as evidenced by recent margin performance and forward guidance.

Want the full story behind that $110 figure? The core of this narrative leans on compounding earnings, firmer margins, and a future earnings multiple that is lower than many peers.

Using an 8.07% discount rate, this framework ties together expected revenue growth, higher long term profit margins and a future P/E assumption to arrive at that $110 estimate, while also factoring in planned share reductions and ongoing dividends.

Result: Fair Value of $110 (UNDERVALUED)

However, this story can change quickly if government agencies accelerate in house automation, or if tight budgets delay contracts and reduce volumes on key programs.

Next Steps

The mix of optimism and concern around Maximus is clear. If the stock has your attention, take a moment now to weigh both sides for yourself and review the 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Maximus has sparked your interest, do not stop here. Broaden your watchlist with other focused ideas that could fit your portfolio and goals.

• Target resilient income by checking out companies that stand out as 13 dividend fortresses.
• Hunt for quality at a potential discount through our curated list of 51 high quality undervalued stocks.
• Prioritize stability by focusing on 67 resilient stocks with low risk scores that aim to keep volatility in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.